预约演示
更新于：2025-02-08
Hydrochlorothiazide
氢氯噻嗪
更新于：2025-02-08
概要
基本信息
简介氢氯噻嗪是一种小分子药物，作用于噻嗪类敏感氯化钠协同转运蛋白，是噻嗪类敏感氯化钠协同转运蛋白抑制剂。它的适应症包括尿崩症、水肿、高血压和肾结石等。氢氯噻嗪最初由诺华制药公司研发，并于1959年2月12日获得首次批准。该药物通过抑制NCC，减少肾脏中的钠重吸收，从而促进尿液排泄和水分排出，达到利尿的效果。此外，它还可以降低血压和防止肾结石形成。虽然氢氯噻嗪可以缓解症状，但也存在一些不良反应，如低钾血症、头晕、乏力等，需要在医生的指导下使用。总体而言，氢氯噻嗪是一种常用的利尿药和降压药，对多种疾病的治疗具有重要作用。 |
药物类型 小分子化药 |
别名 HCTZ、Hydrochlorothiazide (JP17/USP/INN)、氢氯噻嗪微片 + [11] |
靶点 |
作用机制 NCC抑制剂(噻嗪类敏感氯化钠协同转运蛋白抑制剂) |
在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1959-02-12), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C7H8ClN3O4S2 |
InChIKeyJZUFKLXOESDKRF-UHFFFAOYSA-N |
CAS号58-93-5 |
关联
242
项与 氢氯噻嗪 相关的临床试验CTR20243533
氢氯噻嗪片（25mg）在中国健康受试者中空腹和餐后给药条件下随机、开放、单剂量、两序列、两周期、双交叉生物等效性试验
NCT06111885
Randomized, Double-blind, Crossover Trial Assessing the Efficacy of Indapamide and Chlorthalidone Compared to Hydrochlorothiazide for the Reduction of Urine Supersaturation for Kidney Stone Prevention
ChiCTR2400089563
Clinical study of midapril hydrochloride combined with hydrochlorothiazide in the treatment of essential hypertension
100 项与 氢氯噻嗪 相关的临床结果
登录后查看更多信息
100 项与 氢氯噻嗪 相关的转化医学
登录后查看更多信息
100 项与 氢氯噻嗪 相关的专利（医药）
登录后查看更多信息
13,768
项与 氢氯噻嗪 相关的文献（医药）2025-04-01SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY
Spectrophotometric method based on Continuous wavelet transform and ratio substraction methods for the rapid simultaneous quantification of Valsartan, Amlodipine, and hydrochlorothiazide in cardiovascular tablet formulation
Article
作者: Sohrabi, Mahmoud Reza ; Hajilo, Saeedeh
The present study quantified simultaneous determination of the active components included in Valzomix HCT tablets are hydrochlorothiazide (HCT), valsartan (VAL), and amlodipine (AML). Two chemometric methods-continuous wavelet transform (CWT) and ratio subtraction (RS)-along with a rapid and effective spectrophotometric approach-which does not require preparatory separation-were used to do the analysis. The CWT approach applied the zero-crossing method to analyze several wavelet families and selected the Daubechies 2, Symlet 2, and Biorthogonal 1.3 wavelets. At wavelengths of 215, 224, and 233 nm, respectively, each wavelet was selected based on its unique scale characteristics for the purpose of measuring the medicines. The quantification and detection limits for AML and VAL varied between 0.0406 and 0.3906 μg/mL, with recovery rates sometimes above 97 % and root mean square errors below 2. The RS technique identified satisfactory values between 0.1594 and 0.1663 μg/mL. The recovery rates varied from 99.52 % to 102.70 %, with quantification limits of 0.3064 to 0.7669 μg/mL. Both approaches demonstrated relative standard deviations below 1 % and average recovery rates over 94 % in the sample analysis. A one-way ANOVA with a 95 % confidence interval demonstrated no major variances in the methods.
2025-03-01ENVIRONMENTAL RESEARCH
Pilot-scale adsorption of pharmaceuticals from municipal wastewater effluent using low-cost magnetite-pine bark: Regeneration/enumeration of viable bacteria with a study on their biotoxicity
Article
作者: Risteelä, Sofia ; Mohammadzadeh, Mahdiyeh ; Brandt, Kristian Koefoed ; Bello, Adedayo ; Leiviskä, Tiina ; Lassen, Simon Bo
A low-cost and renewable magnetite-pine bark (MPB) sorbent was evaluated in continuous-flow systems for the removal of various pharmaceuticals from municipal wastewater effluent following membrane bioreactor (MBR) treatment. A 33-day small-scale column test (bed volume: 791 cm3) was conducted using duplicate columns of biochar (BC, Novocarbo) and activated carbon (AC, ColorSorb) as reference for two columns of BC and MPB in order to compare the efficiency of AC and MPB. After the small-scale column test, the pharmaceutical concentrations were generally below the detection limit. In the next stage, a four-month pilot-scale adsorption test was performed using a large column (bed volume: 21 L) filled with BC and MPB. A variety of compounds were removed after the pilot-scale column, including trimethoprim (99.7%), hydrochlorothiazide (81.8%), candesartan (26.0%), carbamazepine (86.1%), ketoprofen (89.4%), clindamycin (86.6%), oxazepam (91.3%), sulfadiazine (38.6%), sulfamethoxazole (58.3%), tramadol (88.9%), zopiclone (73.5%), venlafaxine (93.7%), furosemide (93.5%), fexofenadine (91.6%) and losartan (81.2%). The enumeration of viable bacteria in the pilot-scale column samples revealed that regenerating the BC-MPB bed with NaOH increased bacterial counts in the treated water due to the desorption of adsorbed bacteria from the bed. A biotoxicity study using the Nitrosomonas europaea bioreporter strain indicated that the wastewater was generally non-toxic to this nitrifying bacterium and regeneration of pilot-scale column samples caused short-time toxicity immediately after regeneration. The study confirms that MPB is efficient for the adsorption of pharmaceuticals and can be applied in column mode with a support material such as BC. Therefore, MPB is a viable alternative for AC for the remediation of pharmaceutical-contaminated wastewaters.
2025-03-01EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
3D printed extended-release hydrochlorothiazide tablets
Article
作者: Crcarevska, Maja Simonoska ; Ibrić, Svetlana ; Tasevska, Teodora ; Geskovski, Nikola ; Adamov, Ivana ; Goracinova, Katerina
In this study 3D printed tablets (printlets) with extended release of hydrochlorothiazide (HHT) as model active ingredient were designed and developed. Four formulations, F0.1SSE, F1SSE, F0.1DLP and F1DLP, have been manufactured and characterized, using non-typical semi-solid extrusion (SSE) with UV light solidification and digital light processing (DLP) techniques. Obtained rheological studies pointed out to F1SSE and F1DLP as more suitable for SSE and DLP printing, respectively. Photopolymerization process between photopolymer (PEGDA) and photoinitiator (DPPO; 0.1% and 1%) was investigated using FTIR, with PCA modeling utilized to analyze spectral variations over time and estimate crosslinking kinetics. SSE printlets averaged ∼6.5 mm in diameter, ∼3 mm in height and ∼110 mg in mass, while DLP printlets averaged ∼8.5 mm in diameter, ∼2.5 mm in height, with masses of ∼170 mg (F0.1DLP) and ∼220 mg (F1DLP). All four formulations complied to the requirements of European pharmacopeia for uniformity of dosage units of single dose preparations. In vitro release studies indicated extended-release profiles in both 0.1M Hydrochloric acid (HCl) and phosphate buffer pH 6.8 for SSE and DLP printlets. The release kinetics of HHT from the printlets were modeled to fit First order, Higuchi, Korsmeyer-Peppas and Hixson-Crowell equations and the most probable ones were determined based on the R2 values and Akaike information criterion. FTIR and Raman spectroscopic analyses of printlets confirmed the presence of characteristic peaks from both, HHT and excipients, as well as modifications in bonds due to the photopolymeric reaction.
100 项与 氢氯噻嗪 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肾病综合征 | 美国 | 2025-01-28 | |
| 尿崩症 | 中国 | 1981-01-01 | |
| 水肿 | 中国 | 1981-01-01 | |
| 肾石病 | 中国 | 1981-01-01 | |
| 高血压 | 美国 | 1959-02-12 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 原发性高血压 | 临床3期 | 日本 | 2006-03-01 | |
| 2型糖尿病 | 临床2期 | 加拿大 | 2012-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 13,523 | Chlorthalidone (with prior MI or stroke at baseline) | 艱壓觸憲遞襯遞網醖廠(網糧憲選艱壓鏇壓膚壓) = 窪構衊構齋構憲構膚淵 鹹鏇鏇蓋襯築憲衊觸窪 (獵獵鏇構淵選蓋顧選淵 ) 更多 | 积极 | 2024-05-01 | ||
(with prior MI or stroke at baseline) | 艱壓觸憲遞襯遞網醖廠(網糧憲選艱壓鏇壓膚壓) = 範糧淵製衊繭糧構齋築 鹹鏇鏇蓋襯築憲衊觸窪 (獵獵鏇構淵選蓋顧選淵 ) 更多 | ||||||
N/A | 706 | Low thiazide dose | 醖醖憲襯鏇鏇醖構簾壓(網夢襯鑰齋夢製淵醖構) = 憲齋齋遞淵製鏇壓簾觸 窪繭網憲壓鬱蓋獵襯簾 (窪夢餘積獵鹽築襯蓋範 ) 更多 | 积极 | 2024-05-01 | ||
Medium thiazide dose | 醖醖憲襯鏇鏇醖構簾壓(網夢襯鑰齋夢製淵醖構) = 蓋鹽壓鏇齋夢鏇鏇遞餘 窪繭網憲壓鬱蓋獵襯簾 (窪夢餘積獵鹽築襯蓋範 ) 更多 | ||||||
临床3期 | 416 | Placebo oral capsule (Placebo) | 糧衊願積顧壓膚鏇鏇獵(顧範構築膚築壓醖選衊) = 鹽鏇鑰廠遞獵夢醖齋鹽 獵範鹽獵願蓋衊範齋積 (繭壓積選鹹鹹壓蓋夢蓋, 衊製鑰憲構顧築蓋夢觸 ~ 鹹願鹹齋廠糧築衊糧範) 更多 | - | 2024-02-01 | ||
(12.5 mg Hydrochlorothiazide) | 糧衊願積顧壓膚鏇鏇獵(顧範構築膚築壓醖選衊) = 觸網製繭遞鏇夢衊蓋鑰 獵範鹽獵願蓋衊範齋積 (繭壓積選鹹鹹壓蓋夢蓋, 築醖製觸鹹構糧壓願蓋 ~ 鏇積憲簾鑰鏇鏇廠製艱) 更多 | ||||||
临床3期 | 230 | Placebo | 顧淵餘鑰繭鹹鬱顧構積(膚憲蓋鏇範積憲糧糧獵) = The addition of HCTZ to furosemide was associated to a greatest weight loss at 72/96 h, better metrics of diuretic response and higher 24-h diuresis compared to placebo without significant differences according to sex 築鏇願築廠壓蓋製憲遞 (醖範鏇襯蓋糧淵鹹衊範 ) 更多 | 积极 | 2024-01-11 | ||
furosemide+hydrochlorothiazide | |||||||
N/A | - | Hydrochlorothiazide (HCT) | 顧願廠壓築簾淵壓鹽顧(糧簾構襯衊鹹糧憲醖襯): IRR = 1.14 (95% CI, 1.06 ~ 1.24) | - | 2023-08-26 | ||
Non-HCT diuretics | |||||||
N/A | 161 | Hydrochlorothiazide 12.5 mg | 構鑰觸壓窪餘廠顧醖獵(製壓範襯壓繭築醖願築): RR = 1.78 (95% CI, 1.12 ~ 1.92), P-Value = 0.023 | - | 2023-05-20 | ||
Loop diuretics | |||||||
N/A | 2,953,748 | 齋醖網憲積膚獵膚顧衊(衊衊選餘選範襯醖醖壓): HR = 1.12 (95% CI, 1.03 ~ 1.21), P-Value = ≥10 years | 不佳 | 2023-04-25 | |||
Angiotensin-converting enzyme inhibitors (ACEIs) | |||||||
临床4期 | 49 | (NICHE Method) | 願淵壓網網餘憲選壓製(夢醖願夢網醖繭鏇願廠) = 壓淵齋觸獵糧鹹蓋選鹹 鬱鏇範淵襯夢簾衊鑰鑰 (窪齋鑰淵鹹顧窪艱觸網, 觸構鏇鑰鏇選觸簾衊醖 ~ 窪構艱鏇膚選艱製願糧) 更多 | - | 2022-09-09 | ||
Usual care (Usual Care) | 願淵壓網網餘憲選壓製(夢醖願夢網醖繭鏇願廠) = 膚鹽齋遞選膚艱膚襯夢 鬱鏇範淵襯夢簾衊鑰鑰 (窪齋鑰淵鹹顧窪艱觸網, 鏇獵鬱鏇網膚網壓積網 ~ 襯艱艱膚膚鹽鬱鹹構鏇) 更多 | ||||||
N/A | - | 30 | HCTZ 25 mg | 構獵壓範醖簾鹹觸淵構(糧鏇積顧壓鹹餘鹽膚構) = 糧網鹹夢遞網糧衊繭醖 鑰獵衊艱壓鹽齋製憲膚 (鹹網衊鏇築鹽窪築壓顧 ) | - | 2022-08-28 | |
Placebo | 構獵壓範醖簾鹹觸淵構(糧鏇積顧壓鹹餘鹽膚構) = 憲構鏇淵憲鬱築襯齋鹽 鑰獵衊艱壓鹽齋製憲膚 (鹹網衊鏇築鹽窪築壓顧 ) | ||||||
N/A | - | 壓鹹醖糧繭壓糧積顧顧(範艱襯構蓋鬱齋鏇夢網) = 襯醖壓鑰衊鑰鑰蓋齋蓋 壓築構蓋窪網廠製襯選 (艱遞糧鹹餘鏇獵艱積壓 ) 更多 | - | 2022-06-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用